21st Annual Growth Capital Symposium
Presenting Companies
June 4-5, 2002
Interlink Networks
Interlink develops and markets specialized Internet infrastructure products that provide authentication, authorization, and accounting (AAA) solutions, which act as a security gateway to enterprise networks and the Internet.
The company was spun-off from the Merit Network, one of the nations first ISPs, and had initial financing from Siemens Mustang Ventures, Nokia Ventures and Arbor Partners. Interlink is lead by Mike Klein, who was previously the founder and CEO of Steeplechase Software, which was financed by Arbor Partners and was acquired by Schneider Automation, now a part of Entivity.
Asterand
Asterand provides tissue samples to biopharmaceutical companies for research use to address the need for high quality biological information and materials by genomics and proteomics researchers.
The company was founded by Randal Charlton and Oxford Biosciences. Mr. Charlton has led several genetics companies in Europe, as well as medical technology companies in the United States. Previously, he was President and CEO of University Genetics.
QuatRX
QuatRX is developing a portfolio of novel pharmaceutical compounds beginning in the late pre-clinical stage through to completion of Phase II.
QuatRX Pharmaceuticals is a founded by a team of senior executives and scientists formerly with Parke-Davis/ Warner-Lambert, and have developed drugs in diverse therapeutic areas, including Lipitor and Neurontin.
The company was founded in cooperation with Frazier & Company. TL Ventures also participated in the financing.
Nanomed
Nanomed is an advanced drug delivery company developing proprietary Nanotemplate Engineering™ and Thin-Film Composites™ platform technologies to enhance the bioavailability of poorly water-soluble drugs, and enable the targeting of drugs and vaccines to specific cells and tissues.
It is a spin-out based on University of Kentucky research. The company's founders, Dr. Mumper and Dr. Jay, come from the University's Center for Pharmaceutical Science and Technology and its CEO, Mr. Benoit, has extensive background in management in Fortune 300's as well as startups. Most recently he was an Officer and a Member of the USA Executive Management Committee of The Kellogg Company
Exaconnect
Exaconnect is developing and commercializing telecommunication switches based on electronic-beam switching. The company has received $1,000,000 investment from private investors.
Nephrx
NephRX is an early stage biotechnology company developing novel growth factors first developed at the University of Chicago for the treatment of gastrointestinal tract diseases and acute kidney failure.
The company is led by Peter Croden who has more than 30 years of pharmaceutical management experience with the former Upjohn Company (currently Pharmacia Corp.). It recently closed a multi-million dollar partnership with a major pharmaceutical company in late December 2001 and a $750,000 round of financing in February 2002. The round was led by ARCH and includes White Pines Ventures and private investors.
Genetics Squared
G2 is an in-silico discovery company dedicated to producing superior diagnostics, targets, lead compounds and tailored medicines, quickly and cheaply, in collaboration with partners in the pharmaceutical and biotechnology industries and academia. G2 applies its proprietary software and analysis platform, which is based on a patented implementation of Genetic Programming (GP), to discovering commercially valuable information from biological data.
The firm has research collaborations with the University of Michigan, Michigan State University and Wayne State University and is in negotiations with a major pharmaceutical company. The company has received investments from private investors and has a partnership with CrystalPoint Partners.
PanCel
PanCel is an early stage cellular therapy company that has developed technology to genetically engineer pancreatic cell lines, transparent to the human immune system, with the potential to produce insulin for the eventual cure of diabetes. PanCel's founding scientists are leaders in engineering human pancreatic cells.
The company is based on research and intellectual property licensed from the University of California San Diego. Financing was led by Whitepines Ventures. Arch Development Partners have also participated in the financing.
Rubicon Genomics
Rubicon Genomics is an early stage company developing novel means for whole genome amplification and haplotyping, a key to the emerging field of personalized medicine. The company's product is based on the work of the scientific founders and inventions from the University of Michigan.
The company is led by Dr. Thomas Collett, formerly a General Partner of Tullis-Dickerson. Previously, he led the startup of Integrated Protein Technologies, a unit of Monsanto. The company received initial financing from Sloan Ventures and Duchossois Technology Partners. Recently, ARCH Development Partners and Duchossois Technology Partners syndicated a $2.5 million financing for Rubicon.
Verity Biosystems (FKA: Streamline Proteomics)
Verity Biosystems is developing systems to accelerate the high throughput screening of genome and proteome function. The company is commercializing a novel approach to gene research that implement the use of small microspheres (beads) for the analysis of biological gene/drug targets in a research or clinical sample. The company's product line includes instrumentation, consumables and software.
The company is cofounded by Sloan Ventures, who are providing interim management. The company's Chief Science Officer was previously with Genomic Solutions.
Peptide Synthesis Technologies
Peptide Synthesis Technologies is a start-up stage company developing and commercializing an enzymatic synthesis platform for the large-scale manufacture of high purity peptides and proteins for the pharmaceutical and biotechnology industries, the food and agriculture industries and the chemicals industry.
The company is founded by CrystalPoint Partners in partnership with Dr. Michael Young, former Chairman of Biochemistry and Molecular Biology at the University of Florida and former Chairman of the Division of Medical Sciences at Harvard University.
Tal Materials
Tal Materials is a nanotechnology company providing nanopowder-based research and development solutions to corporate customers. TAL's unique flame spray pyrolysis (FSP) technology enables production of a wide variety of complex mixed-metal oxide nanopowders for use in fields that include solid oxide fuel cells (SOFC), catalyst technologies, photonic applications and specialty ceramics.
The company was founded in 1996 as a commercial spin-off from the University of Michigan. The company has raised a seed round of private capital from professional investors led by Steve Swanson, General Partner, Arbor Partners, who also serves as interim CEO.
MC3
MC3 develops devices for cardiopulmonary support. Its core product, BioLung is designed to provide oxygen and carbon dioxide exchange with blood without the need for an external, mechanical pump. The company's technology was highlighted in a recent cover story of Red Herring magazine. The company is in research collaborations with the University of Michigan and the University of Texas.
Orthopedic Development
Orthopedic Development is a startup stage company developing and commercializing a treatment for spinal cord injury. This treatment is based on attaching magnetic nanoparticles to growth cones of injured neurons and the sequential application of a magnetic field, pulling neurons across the injury site. The company is in research collaborations with the Yale University School of Medicine, Stanford Medical School and Michigan State University.
Nexcerpt
Nexcerpt is an early stage information technology company developing novel products for information retrieval and publication.
The company is led by Julie Stock who co-founded and served as CEO of InGenius Technologies, Inc., a firm specializing in change monitoring and intelligence gathering which was acquired by EoExchange in 1999.
The company is financed by Greenleaf Capital and ARCH Development Partners.
zuChem
zuChem is a start-up stage company formed to commercialize company and university technology in the field of carbohydrate based pharmaceutical intermediates.
The company is led by David Demirgian who previously founded of Thermogen, a biocatalysis company, which was recently acquired by MediChem. Arch Development Partners is leading the series A round.
Please contact the Center at 734-936-3528 for more information or e-mail us at CVPUMBS1@umich.edu.
RETURN TO TOP
|
